

Cleavage and Inactivation of Factor IX by Granulocyte Elastase

AKIRA TAKAKI, DAVID L. ENFIELD, and ARTHUR R. THOMPSON, *Department of Medicine, University of Washington and Seattle Public Health Hospital and the Puget Sound Blood Center, Seattle, Washington 98144*

ABSTRACT Radioiodinated Factor IX was cleaved by a crude sonicate from leukocytes. In the absence of calcium, fragments of <15,000 mol wt were seen from reduced samples on gel electrophoresis. After digestion in 2 mM calcium, however, electrophoresis of reduced samples showed, in addition to low molecular weight fragments, protein bands corresponding in size to heavy and light chains of Factor XIa-activated Factor IX. The cleaving activity in leukocyte sonicates was inhibited by soybean trypsin inhibitor, but only to a small extent by aprotinin.

Granulocyte elastase was isolated from purified polymorphonuclear leukocyte granules by affinity chromatography on soybean trypsin inhibitor-agarose and further chromatography on carboxymethyl cellulose. The purified fraction contained two isozymes on acidic gels which cleaved both an ester sensitive to elastase and radiolabeled Factor IX. These two activities were inhibited by elastase-specific chloromethyl ketone. The isolated protease fraction rapidly inactivated apparent Factor IX activity in a coagulant assay system. The degree of inactivation correlated with the amount of intact, radiolabeled Factor IX cleaved. As with the crude sonicate, generation of the larger heavy and light chain-sized fragments was dependent upon calcium.

To assess directly the effect of elastase on Factor IX, an immunospecific, active site-directed assay was developed. In this assay, the sample was incubated with solid-phase antibody to Factor IX and the amount of activated product was detected as that which had complexed with radioiodinated antithrombin III. In this

system, exposure of Factor IX to Factor XIa showed progressive increase in the ability to bind antithrombin III, whereas after elastase, Factor XIa was unable to generate antithrombin III binding. The elastase-degraded Factor IX did not inhibit activation of additional Factor IX in clotting assays. When Factor IXa was incubated with elastase, binding of antithrombin III was decreased, corresponding to appearance of low molecular weight fragments on parallel samples that were reduced and electrophoresed. These data are consistent with elastase inactivating Factor IX by cleaving bonds near, but distinct from, bonds cleaved by Factor XIa.

INTRODUCTION

It is well established that Factor XIa activates Factor IX by two activation cleavages (1). However, no plasma cofactor or means of achieving a sufficient local concentration of these trace plasma proteins has been identified. Under some conditions, it has also been shown that Factor VIIa with tissue factor cleaves Factor IX (2), but the significance of this proteolysis has not been well established. Even less is known about the susceptibility of Factor IX or IXa to degradative cleavages, although partial degradation would serve as a potent means of limiting the coagulation response at an early stage.

In contrast to a system of proteolysis composed of interactions between plasma proteins, physiologic or pathologic cleavage of Factor IX could occur by cellular neutral proteases. This possibility was suggested by data of Kingdon et al. (3) who noted generation of a Factor IXa-like procoagulant activity when a crude concentrate containing Factor IX was incubated with a granulocyte sonicate. The degree of activation, however, could not be assessed by their clotting assays which would have been sensitive to modification of Factor VIII or other effects upon their generated Factor IXa-like activity. Furthermore, their activity re-

Dr. Takaki's present address is the University of Occupational and Environmental Health, School of Medicine, Yahata Nishi Ku, Kitakyushu 807 Japan. Address correspondence to Dr. Thompson.

Received for publication 3 January 1983 and in revised form 10 June 1983.

quired a plasma protein fraction as a cofactor, conceivably to prevent inactivation of Factor IX.

Probably the major neutral protease from granulocytes is an elastase. In patients with disseminated intravascular coagulation, high levels of granulocyte elastase were detected in plasma, complexed to α_1 -antitrypsin (4). Indeed, this elastase is released during *in vitro* clotting of whole blood or even recalcified plasma enriched with isolated neutrophils (5). Elastase would thus be available to cleave clotting factors, at least at local sites of inflammation, before its inactivation.

In approaching the problem of Factor IX proteolysis by granulocytic enzymes, we initially found that crude granulocyte preparations would cleave ^{125}I -Factor IX to yield either low molecular weight peptides or, in the presence of calcium, heavy chain and light chain-sized fragments, suggestive of activation.¹ As an extension of this preliminary observation, we have now examined the effect of granulocyte elastase on Factor IX in an isolated system. Electrophoresis of reduced ^{125}I -Factor IX samples was used as an index of cleavage. Because there has been no specific functional assay for Factor IXa, an immunospecific, radiolabeled-inhibitor assay was developed to test for generation of the Factor IX active site.

METHODS

Materials. Chemicals were purchased from the following sources: Coomassie Brilliant Blue (R-250), Methyl Green, acrylamide, *N,N'*methylenebisacrylamide, *N,N,N,N'*tetramethyl-ethylene diamine, sodium dodecyl sulfate, ammonium persulfate, carboxymethyl (Cm)² cellulose (Cellex-CM), and lactoperoxidase-glucose oxidase reagent (Enzymobead) from Bio-Rad Laboratories, Richmond, CA; Sepharose 4B and Sephadex G-25 and G-75 from Pharmacia Fine Chemicals, Piscataway, NJ; Ficoll (Histopaque-1077), dextran (industrial grade, 161,000 average mol wt), trypsin inhibitor (type I-S from soybean), *N* α -*p*-toluenesulfonyl (Tos)-L-Lys chloromethyl ketone, L-1-tosylamide-2-phenyl-ethyl chloromethyl ketone, *N*-benzoyl (Bz)-L-Tyr ethyl ester, *N*-benzyloxycarbonyl (Cbz)-L-Lys-*p*-nitrophenyl ester, *N*-*tert*-butoxycarbonyl (t-BOC)-L-Ala-*p*-nitrophenyl ester, heparin, bovine albumin (fraction V), rabbit brain cephalin, porcine pancreatic elastase (type I), α_1 -antitrypsin, and dithiothreitol, Sigma Chemical Co., St. Louis, MO; [^{125}I]sodium iodide (2 mCi/20 μl), New England Nuclear, Boston, MA. Factor IX was isolated from plasma and radioiodinated as previously described (6) and the following were generous gifts from sources as in-

dicated: methoxy (MeO)-succinyl(Suc)-Ala-Ala-Pro-Val chloromethyl ketone (7), Dr. James C. Powers, Georgia Institute of Technology, Atlanta, GA; human Factor XIa (8) and human antithrombin III-heparin complex (9), Dr. Kotoku Kurachi, and affinity-purified goat anti-human Factor IX,³ Dr. Walter Kisiel, both of the Department of Biochemistry, University of Washington. Tris-buffered saline was composed of 0.1 M NaCl in 50 mM Tris-HCl, pH 7.5 (unless otherwise indicated).

Preparation of granule extracts. The preparation of granule extracts was adapted from the method of West et al. (11). Granulocyte-rich fractions were isolated from buffy-coat layers prepared from whole blood of consenting, normal donors and purchased from the Puget Sound Blood Center. The preparations contained citrate-phosphate-dextrose with adenine. Buffy-coat layers from four units of whole blood were pooled, yielding an average of 240 ml of packed cells; heparin (20 U/ml) was then added, followed by 200 ml of 0.15 M NaCl. Within 6 h after being drawn, cells were sedimented in $\frac{1}{2}$ vol of Ficoll reagent under a centrifugal force of 400 *g* for 30 min. After discarding the supernatant layers, a volume of 3% dextran twice that of the starting cell fraction was aliquoted in equal volumes into the centrifuge tubes and mixed; the erythrocytes were then allowed to sediment at room temperature for 30 min. By centrifuging at 400 *g* for 10 min, leukocytes with some erythrocyte contamination were collected from the supernate. Hypotonic lysis of the remaining erythrocytes was accomplished in three cycles of alternatively washing with equal volumes of 0.2 and 1.6% NaCl. From the final centrifuged precipitate, the granulocytes were resuspended in 20 ml 0.34 M sucrose with 10,000 U heparin and lysed by aspiration and expression 18 times through a 20-gauge needle. Cellular debris was removed by centrifugation at 1,000 *g* for 10 min. The granule fraction was obtained as a pellet from a second centrifugation at 28,000 *g* for 30 min; the pellets were resuspended in 4 ml Tris-buffered saline and stored at -80°C . Three preparations from 4 U of granulocyte-rich fraction were combined and sonicated in a Bransonic-12 water bath for 3 min and then centrifuged at 40,000 *g* for 30 min. The pellets were resuspended in 30 ml Tris-buffered saline and frozen and thawed five times to ensure granule membrane lysis. Granule supernatants obtained subsequent to freezing, thawing, and centrifugation (40,000 *g* for 30 min) were combined and dialyzed against Tris-buffered saline.

Isolation of elastase isozymes. Affinity and ion-exchange chromatography were performed similarly to the method of Baugh and Travis (12), except soybean trypsin inhibitor was used as the affinity ligand instead of aprotinin. Soybean trypsin inhibitor-agarose was prepared by CNBr activation (6) of 50 ml Sepharose 4B, followed by stirring overnight with 1 g soybean trypsin inhibitor at 4°C . Columns (2.5 \times 4 cm) of resin were equilibrated with Tris-buffered saline and the sample of lysed granules from 12 U of buffy coat applied. The column was consecutively washed with 100 ml each of Tris-buffered saline and 0.5 M NaCl in 50 mM Tris (pH 7.5). Crude elastase was eluted with 50 ml 0.1 M acetic acid. After dialysis against 0.15 M NaCl in 10 mM sodium acetate (pH 5.6), the crude preparation was applied to a Cm-cellulose column (1 \times 20 cm) equilibrated with the same buffer. After a 150-ml wash with start buffer (to an A_{280} below 0.01), a

¹ A preliminary investigation on the effects of granulocyte sonicates and granule fractions has been presented (Thompson, A. R., A. Takaki, D. L. Enfield, and D. G. Wright. 1980. *Clin. Res.* 28:326A).

² Abbreviations used in this paper: Bz, benzoyl; Cbz, benzyloxycarbonyl; Cm, carboxymethyl; MeO, methoxy; Suc, succinyl; t-BOC-, *tert*butoxycarbonyl; Tos, *p*-toluenesulfonyl.

³ Purified by Dr. Kisiel as described for alloantibodies (10), the preparation migrated as homogenous IgG on polyacrylamide gels in sodium dodecyl sulfate.

linear gradient consisting of 250 ml each of 0.15 M and 0.3 M NaCl, both in 10 mM sodium acetate, pH 5.6, was run. Compared with other preparations (12), a lower NaCl concentration was used in the final buffer to minimize potential contamination. Final Cm-cellulose fractions were concentrated by chromatography on soybean trypsin inhibitor-agarose columns with elution in 0.1 M acetic acid followed by dialysis against Tris-buffered saline. Purity was assessed by disc-gel electrophoresis at pH 4.5 (13) on 15% polyacrylamide gels containing 0.1% sodium dodecyl sulfate.

Factor IX cleaving activity. Cleavage of Factor IX was carried out in dilute solutions containing 2 μ g unlabeled Factor IX and to 20,000 cpm 125 I-Factor IX in 100- μ l final volumes. Factor XIa or elastase was added in Tris-buffered saline at 37°C. Typically, enzyme to substrate ratios were 1:75 and 1:10, respectively; CaCl₂ was added to a final concentration of 2–6 mM. Reactions were stopped by either sodium dodecyl sulfate with or without dithiothreitol (14), antithrombin III with heparin, or α_1 -antitrypsin. Samples with sodium dodecyl sulfate were incubated overnight at 37°C, and run on 10% polyacrylamide gels containing 0.1% sodium dodecyl sulfate (15). Gels were sliced in an electric gel slicer (2.0 mm; Bio-Rad Laboratories model 195) and slices counted in a Nuclear Chicago Gamma Counter (Chicago, IL; model 1085, 80% efficient). For some experiments, 2.5-mm slices were prepared by hand.

Factor IXa-antithrombin III binding assay. Labeling of antithrombin III with lactoperoxidase-glucose oxidase reagent was carried out according to the manufacturer's instructions. Typically, 25 μ g human antithrombin III (1 mg/ml) complexed with heparin (9) was labeled with 1 mCi [125 I]sodium iodide at ambient temperature for 10–20 min. The mixture was desalted on a 10-ml column of Sephadex G-25 (medium) that had been prewashed with 2 ml of 10% bovine albumin in Tris-buffered saline and rinsed with 10 ml of the same buffer without the albumin. The reaction mixture was applied to this column and was then eluted with Tris-buffered saline.

For the assay, purified goat anti-Factor IX, which contained 19 mg/ml protein and 800 Bethesda inhibitor U/ml, was diluted 1:500 in 0.1 M NaHCO₃ (pH 9.5) and 100 μ l was incubated for 1 h at 37°C in microtiter wells (Imulon-I Removawell Strips, Dynatech Laboratories, Inc., Alexandria, VA). After incubation, wells were washed three times with Tris-buffered saline containing 0.1% albumin. Unlabeled Factor IX was incubated with enzymes as indicated above in the cleaving assay; reactions were terminated by diluting an aliquot into an excess of 125 I-antithrombin III with heparin. The Factors IX and/or IXa-antithrombin III mixtures were then diluted to 120 μ l with 0.1% albumin in Tris-buffered saline, and 100 μ l transferred to the antibody-coated wells; incubations were 2–6 h at room temperature. After this incubation, wells were washed three times with Tris-buffered saline containing 0.1% albumin and counted. Percentage binding was determined from precoupling of the wells before washing. For some assays, EDTA or α_1 -antitrypsin were added.

Enzyme assays. Elastase activity was determined by the spectrophotometric method of Visser and Blout (16) using *N*-t-BOC-L-Ala-*p*-nitrophenyl ester as the substrate; the procedure was performed in phosphate buffer at pH 6.5 and 30°C, using a Gilford spectrophotometer with auto cuvette positioner and recorder (models 252, 2451-A, and 6051, respectively, Gilford Instrument Laboratories, Inc., Oberlin, OH). One unit of activity was arbitrarily defined as the release of 1 μ mol *p*-nitrophenol min⁻¹ml⁻¹ and activity was recorded as $\Delta A_{347.5}$ min⁻¹. Under these conditions, a 1% change in

elastase concentration was detectable. The hydrolysis of *N*-Bz-L-Tyr ethyl ester was determined by the method of Hummel (17) and, the *N*-Cbz-L-Lys-*p*-nitrophenyl ester by the method of Silverstein (18). Protein concentrations were calculated from A₂₈₀ with $E_{1\text{cm}}^{1\%}$ values of 9.85 and 13.3 for elastase (12) and Factor IX (19), respectively. For routine inhibitor studies, granulocyte enzyme fractions were incubated with a final concentration of 1 mM L-1-tosylamide-2-phenylethyl chloromethyl ketone, Tos-L-Lys chloromethyl ketone, or MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone at 4°C for 18 h before dilution for esterolytic assays or determination of 125 I-Factor IX digesting activity.

Factor IX clotting activity and inhibition were determined by the one-stage partial thromboplastin time with kaolin and deficient plasma as previously described (6). For Factor IXa coagulant activity, kaolin was omitted and substrate plasma, phospholipid, and sample were warmed for 15 s at 37°C before recalcification; tipping in siliconized glass tubes and reagents were as otherwise described for the assay with contact activation (6). In testing for inhibition of Factor IX coagulant activity, elastase-degraded Factor IX was added to normal and Factor IX-deficient plasmas before the kaolin activated, one-stage assay.

RESULTS

After the separation of leukocytes and hypotonic lysis of erythrocytes, granulocytes represented 96% of the white cells on the basis of differential cell counts. In preliminary experiments, granule extracts were found to digest 125 I-Factor IX into peptides and fragments of mol wt <15,000. However, when cleavage was performed in the presence of 2 mM calcium, and the reduced samples electrophoresed, half of the radioactivity appeared in bands of higher molecular weight. These corresponded in size to the heavy and light chains of Factor XIa-activated Factor IX (see Fig. 1). For subsequent studies, CaCl₂ was included in digests of 125 I-Factor IX. Additionally, upon incubation of Factor IX with the crude granule preparations in the presence of aprotinin, only 10% of 125 I-Factor IX remained uncleaved as compared with 65% or more when comparable amounts of soybean trypsin inhibitor were added (Fig. 2). This effect of soybean trypsin inhibitor provided the rationale for its use in the purification scheme.

Purification and characterization of human granulocyte elastase. Upon fractionating the crude granule lysate preparation on soybean trypsin inhibitor-agarose, one-third of the applied protein was found each in the breakthrough peak, the NaCl wash, and the acetic acid eluate. Factor IX degrading activity was confined to the acid eluate as was hydrolyzing activity against *N*-t-BOC-L-Ala-*p*-nitrophenyl ester, the elastase substrate. This eluate fraction failed to cleave the tyrosyl or lysyl esters tested (see Methods). During Cm-cellulose chromatography at 4°C, the majority of the protein did not bind and eluted before the start of the linear gradient.




FIGURE 1 Cleavage of Factor IX by Factor XIa. Factor IX (25 μg), containing a trace of ^{125}I -Factor IX, was incubated at 37°C for 1 h with 0.5 μg Factor XIa in Tris-buffered saline containing 2 mM calcium chloride. The samples were then electrophoresed on 10% polyacrylamide in the presence of 0.1% sodium dodecyl sulfate; the anode is to the right. Upper panel shows a stained gel (N) of a nonreduced sample above a profile of the corresponding counts from gel slices, indicating 75% cleavage. Lower panel shows a stained gel (R) of a reduced sample and corresponding counts from the slices. For reference, letters indicate migration distances of nondigested Factor IX (N), heavy (H), and light (L) chains and the dye marker (M, arrow). On more heavily loaded gels (not shown), with protein or carbohydrate staining, the activation peptide was visualized as a broad, lightly staining band between 70 and 80 mm; it did not radioiodinate.

Three smaller peaks were demonstrated by absorbance at 280 nm during gradient elution of four separate preparations. All four Cm-cellulose fractions (the breakthrough and three elution peaks, subsequently referred to as fractions I-IV, respectively) contained Factor IX digesting and elastase-like esterase activity. Fraction I was further purified on G-75 Sephadex where elastase and Factor IX cleaving activities were confined to the void volume; lower molecular weight proteins and peptides were inactive in both assays. Fraction IV showed two distinct bands (Fig. 3) upon disc-gel electrophoresis at pH 4.3. Nonfixed gels, which had been run at the acidic pH, were sliced and eluted into Tris-buffered saline (0.2 ml for each 1-mm slice); each of the two peaks contained elastase-like esterase (Fig. 3) and ^{125}I -Factor IX-cleaving activities. On gel electro-

phoresis, fraction I contained a single broad band from 10 to 13 mm migration, fraction II had a doublet of bands at 12 and 13 mm, and fraction III yielded a banding pattern with features of both fractions II and IV (not shown).

The elastase fractions were further characterized by their interactions with chloromethyl ketones. Using the sensitive *N*-t-BOC-L-Ala-*p*-nitrophenyl ester assay for elastase activity, 27 and 25% inhibition of the activity of fractions I and II, respectively, were obtained with the chymotrypsin inhibitor, tosyl-amide-2-phenylethyl chloromethyl ketone, whereas the trypsin inhibitor, $\text{N}\alpha$ -Tos-L-Lys-chloromethyl ketone, inhibited only fraction I, reducing its activity by 18%. These two inhibitors had no effect upon the esterase activity of fraction IV. However, with MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone, the specific inhibitor of elastase (7), 73-75% inhibition of the initial esterase activity of all fractions was obtained. These results suggest that Cm-cellulose fractions I and II were contaminated with traces of a chymotrypsin-like enzyme and that fraction I also contained a trypsin-like enzyme. Attempts to isolate the latter by chromatography on lysyl-agarose were unsuccessful. The effects of these inhibitors on cleavage of Factor IX by the elastase fractions are shown in Table I. Inhibition of the esterase of fraction IV by MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone was studied further. Isozymes eluted from gels (see Fig. 3), and a separate incubation (1.5 μg elastase in 100 μl) were >99% inhibited after 2-h incubations at 37°C with a 1 mM final concentration of the specific inhibitor.




FIGURE 2 Digestion of ^{125}I -Factor IX by a crude granulocyte sonicate. Incubation and electrophoresis were performed as in Fig. 1, except that the samples were digested with granule sonicate, in the presence (○) or absence (●) of soybean trypsin inhibitor. The samples were reduced before electrophoresis.




FIGURE 3 Granulocyte elastase fraction IV. Electrophoresis was on 15% polyacrylamide disc gels in sodium dodecyl sulfate at pH 4.3. The two bands on the gel (top) correspond to the location of esterase activity as determined on a gel run in parallel, then sliced, eluted in Tris-buffered saline, and assayed. Hydrolysis of *N*-t-BOC-L-Ala-*p*-nitrophenyl ester was recorded as the change in absorbance at 347.5 nm/min compared with a nonenzyme control. Two additional preparations of Cm-cellulose fraction IV were tested and gave the same results. The arrow indicates the position of the marker dye.

Cm-cellulose fraction IV, containing two elastase isozymes, was used for subsequent studies. In the esterase assay, 1:35 μg fraction IV had 1.38 arbitrary units in the *N*-t-BOC-L-Ala-*p*-nitrophenyl ester assay.

In comparison, 10 μg porcine pancreatic elastase contained 0.98 u.

Effects of granulocyte elastase on Factor IX. In a preliminary experiment, it was shown that within 1 min, 1 μl normal plasma completely inhibited the *N*-t-BOC-L-Ala-*p*-nitrophenyl esterase activity of fraction IV (1 μg in 10 μl). To assess the effects of elastase on Factor IX coagulant activity, a purified Factor IX sample was incubated with elastase and aliquots were diluted into Factor IX-deficient plasma, thereby using the plasma protease inhibitors to inactivate the granulocyte enzyme. Clotting activities were then determined and are shown in Fig. 4. The incubation mixtures contained unlabeled and a trace of ^{125}I -labeled Factor IX. In addition to dilution of aliquots into plasma for determination of coagulant activity, aliquots were also taken at 10 min, reduced, and run on 10% polyacrylamide gels in sodium dodecyl sulfate. After slicing, 28% of the label remained in the uncleaved Factor IX position, in good agreement with the 25% remaining coagulant activity at this time. In separate experiments, the proteolysis of ^{125}I -Factor IX by fraction IV showed the same calcium-dependent specific cleavages (Fig. 5) as previously found when the crude granulocyte preparation was used. As before, in the absence of calcium, only fragments of <15,000 mol wt were obtained.

TABLE I
Effects of Chloromethyl Ketone Inhibitors on Factor IX Cleavage
by Elastase Fractions

Factor IX peak (mm)*	Fraction I		Fraction II		Fraction IV			
	None	E-CMK	None	E-CMK	None	E-CMK	TPCK	TLCK
Uncleaved (17-20)	24	51	15	91	14	63	14	15
Intermediate (21-26)	21	21	20	7	5	21	5	3
Heavy chain (33-38)	8	4	11	0	15	5	13	15
Light chain (43-50)	34	19	38	2	33	9	41	39
Fragments (>51)	13	5	16	0	33	2	27	28

Elastase fractions were incubated 24 h at 4°C in 1 mM inhibitor and then diluted 75-150-fold in a final cleavage mixture that contained 2 μg Factor IX with trace ^{125}I -Factor IX and was incubated 30 min at 37°C in Tris-buffered saline with 5 mM CaCl_2 (final volume 50 μl). Cleavage is expressed as percent counts per minute in each peak for reduced samples on 10% polyacrylamide gels electrophoresed in sodium dodecyl sulfate (see Fig. 1 legend). From 70 to 85% of the 3-5,000 cpm applied were recovered and an average of 95% of these were present in the slices indicated; percents in vertical columns were adjusted to 100% of counts present in the indicated peaks.

Abbreviations used in this table: E-CMK, MeO-Suc-Ala-Ala-Pro-Val chloromethyl ketone; TPCK, L-1-tosylamide-2-phenylethyl chloromethyl ketone; and TLCK, α -Tos-L-Lys chloromethyl ketone.

* Peaks typically migrated within the millimeters of gel specified when the marker dye front migrated 80 mm toward the cathode (total gel lengths were near 100 mm). Fragments, however, varied from representing two distinct peaks to a single, broad zone of radioactivity beyond the light chain peak.




FIGURE 4 Inactivation of Factor IX coagulant activity by elastase. Factor IX was incubated with Cm-cellulose fraction IV in 1:5 (○) or 1:10 (●) elastase to Factor IX ratios. At timed intervals, twenty-fold dilutions into Tris-buffered saline were made and the Factor IX clotting activity of a 0.1-ml aliquot determined. Activity was compared with a standard curve determined with normal pooled plasma; the control (□) represents Factor IX without elastase; elastase alone at this dilution had no effect on a partial thromboplastin time of normal plasma (not shown).

To explore whether a Factor IXa species was formed either partially or transiently during cleavage by fraction IV, an immunospecific, labeled-inhibitor assay was used. It had been shown that (a) Factor IX itself would not bind ^{125}I -antithrombin III; (b) during incubation with Factor IXa, a time-dependent increase of binding of the labeled inhibitor was observed; and (c) at its lower limit, the assay could detect as little as 2 ng Factor IXa in volume of 0.1 ml (20, 21).

In preliminary experiments, elastase incubated with unlabeled Factor IX at an enzyme to substrate ratio of 1:10 showed no binding of ^{125}I -antithrombin III. In control experiments with Factor IXa, however, it was noted that elastase itself could interfere with the assay. This interference was not because of effects on the antibody-coated wells, as preincubations of elastase in the wells did not decrease the ability of the antibody to bind ^{125}I -Factor IX. Adding a 10-fold excess of α_1 -antitrypsin to elastase-treated Factor IXa before (as opposed to after) incubation with ^{125}I -antithrombin III did prevent decrease in binding of the complex to the solid-phase antibody. This same excess α_1 -antitrypsin inhibited >99% of the elastase esterase activity after a similar 10-min incubation at 37°C. In subsequent experiments, α_1 -antitrypsin was added before antithrombin III-heparin unless otherwise indicated.

To control for any effects of α_1 -antitrypsin on elastase cleavage of Factor IX, digestion of ^{125}I -Factor IX was repeated on inhibited samples as shown in a time course experiment in the left portion of Table II. Incubations without trace-labeled ^{125}I -Factor IX were run in parallel and elastase-inhibited, degraded Factor IX mixtures were incubated with ^{125}I -antithrombin III. No radioactivity could be detected by the solid-phase anti-Factor IX antibody, as shown in the upper entry in Table III. To exclude the possibility that lack of binding ^{125}I -antithrombin III after elastase digestion may have been because of nonspecific inhibition by α_1 -antitrypsin, the binding experiment was repeated substituting the elastase-specific chloromethyl ketone inhibitor (at a concentration of 10 mM for 10 min) for the α_1 -antitrypsin. After the addition of ^{125}I -antithrombin III, again the binding of radioactivity remained at background levels. Thus, despite the generation of heavy and light chain-like sized peptides (Table II), no binding of ^{125}I -antithrombin III occurred.

Factor IXa was studied to compare effects of elastase on the zymogen and its active enzyme. In studying clotting activity (using Factor IX-deficient plasma for substrate and elastase inhibition and no contact phase activators) 2- μl aliquots of Factor IXa decreased the clotting times of the final 302 μl assay from 67 to 82 s, but clotting remained at that level after both 10- and 20-min incubations. For these studies, elastase to Factor IXa ratios were 1:8.

The effects of elastase on Factor IXa were further studied by examining patterns of reduced samples of




FIGURE 5 Cleavage of ^{125}I -Factor IX by elastase. Factor IX (1 μg), containing a trace of ^{125}I -Factor IX, was incubated at 37°C for 30 min with Cm-cellulose fraction IV at a 1:10 elastase to Factor IX ratio. Incubation was carried out in Tris-buffered saline, pH 7.75, in the presence (●) or absence (○) of 6 mM calcium chloride. The samples were reduced and electrophoresed and the gels sliced and counted as described for Fig. 1 and in Methods.

TABLE II
Cleavage of ¹²⁵I-Factor IX and ¹²⁵I-Factor IXa by Elastase; Gel Electrophoresis of Reduced Samples in Sodium Dodecyl Sulfate

Peak	¹²⁵ I-Factor IX					¹²⁵ I-Factor IXa				
	10 s	5 min	10 min	20 min	60 min	10 s	5 min	10 min	20 min	60 min
Uncleaved Factor IX	42	0	0	0	0	23	0	0	0	0
Intermediate	17	8	3	0	0	16	6	5	0	0
Heavy chain	10	25	24	32	21	17	27	27	26	23
Light chain	18	32	29	6	4	26	29	29	28*	20*
Fragments	13	35	44	52	75†	18	38	39	46	57†

Peak slices (in millimeters), recoveries, and calculations of percent of counts per minute are expressed as described in notes to Table I. For these studies, ¹²⁵I-Factors IX or IXa were incubated with elastase as described in the Methods. At the times given (10 s–60 min), a 10-fold excess by weight of α_1 -antitrypsin to elastase was added for 10 min at 37°C to inhibit the granulocyte protease. Samples were reduced with dithiothreitol (13) and electrophoresed on 10% polyacrylamide gels in sodium dodecyl sulfate as described in the text. Parallel, timed incubations (without labeled clotting factor) were taken and incubated with ¹²⁵I-antithrombin III for the immunospecific Factor IXa assay (see Table III).

* Although distinct peaks were observed within these light chain regions, the radioactivity peak was 4 mm (two slices) more anodal than in the previous cleavages indicating a somewhat smaller size.

† At 60-min digestion, fragments included ~40 and 30% of total counts that migrated beyond the marker dye for Factors IX and IXa, respectively (i.e., counts between 80 and 90 mm toward the cathode on 100-mm gels).

¹²⁵I-Factor IXa on gels as shown in the right portion of Table II. For these particular preparations of Factor IX, ¹²⁵I-Factor IX and Factor XIa, approximately one-fourth of the ¹²⁵I-Factor IX remained uncleaved after 1-h incubation with Factor XIa, the latter at a 1:60 enzyme to substrate ratio. The time-dependent increase of low molecular weight fragments (<15,000 mol wt,

or those migrating further than the light chain) were quite similar to results with ¹²⁵I-Factor IX, including the presence of radioactivity migrating beyond the marker dye after 1 h of digestion with elastase. As with Factor IX, parallel experiments in which ¹²⁵I-Factor IX was omitted were run for Factor IXa to assess antithrombin III binding. As shown in Table III, there was a gradual decline of the ability to bind antithrombin III that corresponded, at least roughly, to the decrease in Factor IXa clotting activity in separate experiments described above.

TABLE III
Binding of ¹²⁵I-Antithrombin III to Elastase-degraded Factors IX and IXa

Preparation	Incubation time				
	10 s	5 min	10 min	20 min	60 min
Factor IX	86 (0.9)	74 (0.8)	65 (0.6)	76 (0.8)	76 (0.8)
Factor IXa	790 (8.9)	666 (7.0)	689 (7.7)	635 (7.0)	550 (5.9)

Results are expressed as counts per minute bound (over background) and, in parentheses, percent, of the counts bound (vs. precounted wells). Controls with Factor IX before elastase incubation or with albumin instead of the clotting factor ranged from 0.7 to 0.9% ¹²⁵I-antithrombin III bound. After Factor XIa activation, again without elastase, Factor IXa gave 8.5% binding on simultaneous controls with the same preparation of labeled inhibitor. An average of 9,550 cpm were added and duplicate determinations ($n = 10$ pairs) varied by an average of 5% for Factor IXa, and for Factor IX, 9% of the counts per minute bound.

These experiments were set up in parallel with those in Table II, although the trace label with ¹²⁵I-Factor IX was omitted and (after the 10-min incubation with α_1 -antitrypsin) samples were incubated with ¹²⁵I-antithrombin for 10 min and then for 2 h at 23°C in anti-Factor IX-coated wells as described in the text.

Possible inhibitory effects of elastase-degraded Factor IX upon Factor IX procoagulant activity were screened as follows. Factor IX was digested by elastase (as in the left-hand portion of Table II) for 60 min and dilutions were added to plasmas at levels of 1/10 (50 ng/ml), equal to (500 ng/ml), and in 10-fold excess of (5 μ g/ml) the concentration of Factor IX in the initial 1:10 normal plasma dilution as added to the Factor IX assay. Parallel gels with ¹²⁵I-Factor IX showed complete cleavage of the intact protein. There was no difference in the Factor IX clotting activity in the normal plasma dilution curve with the degraded Factor IX at any of the three concentrations vs. the normal plasma control without added, digested Factor IX. Furthermore, samples from each of the three levels of degraded Factor IX, added to Factor IX-deficient plasma without any normal plasma, gave kaolin clotting times identically prolonged to those of controlled substrate plasmas (170 s). These latter results indicate plasma "contact activation product" did not generate Factor IXa coagulant activity from the degraded Factor IX.

The ability of Factor XIa to generate antithrombin III binding sites from elastase-degraded Factor IX was then assessed. Elastase was preincubated with Factor IX in Tris-buffered saline with 2.5 mM Ca⁺⁺. After timed incubations at 37°C, excess α_1 -antitrypsin was added. Factor XIa (1:50 enzyme to substrate ratio) was then added and incubated 30 min at 37°C and the reaction stopped with EDTA (5 mM final concentration) and ¹²⁵I-antithrombin III for 10 min at 37°C. The mixture was then incubated in the antibody-coated wells for 2 h at 23°C before washing and counting. For the 10-min and 20-min elastase incubations, 4.1 and 1.7%, respectively, of the excess ¹²⁵I-antithrombin III was bound. These are compared with a 9.9% value for the simultaneous control without elastase and 0.8% for the control without Factor XIa. Thus, despite the failure to demonstrate generation of Factor IXa coagulant activity, Factor XIa could form active sites in elastase-degraded Factor IX that were capable of binding antithrombin III-heparin. Furthermore, this effect of Factor XIa was limited by the degree of prior digestion with elastase.

DISCUSSION

Although cleavage of Factor IX by granulocyte elastase shows generation of fragments of a similar size to those seen with activation by Factor XIa, clotting activity and antithrombin III binding assays indicate that Factor IX is readily inactivated by this cellular neutral protease. The calcium requirement for the more specific Factor IX cleavages is consistent with other data (22, 23) suggesting a calcium-dependent stabilized conformation for Factor IX. As elastase is released from neutrophils during *in vitro* clotting (5) and since enzymes released on cellular contact have been shown to digest other proteins such as fibronectin (24), it is conceivable that sufficient quantities of elastase could be generated to inactivate Factor IX, or, for that matter, other coagulation proteins, particularly at local sites of inflammation. To test the significance of this reaction, it would be necessary to examine the relative degradation rates of different factors in more complex *in vitro* systems. In the presence of other protein substrates and enzymes, the cleavage of Factor IX vs. other coagulation factors could be assessed. With these qualifications, it remains plausible that Factor IX degradation by cellular neutral proteases represents a control mechanism for coagulation.

Assessment of activation by using either electrophoretic patterns of cleaved, reduced ¹²⁵I-Factor IX samples (25) or the generation of trichloroacetic acid-soluble ³H-carbohydrate activation peptide (26) depends only on physical changes. In dealing with proteases of

broader specificity or in more complex reaction mixtures, mere cleavage is not equivalent to activation. As shown with granulocyte elastase, cleavage was associated with destruction of Factor IX coagulant activity. In studies by others, Factors IX and IXa were inactivated by an elastase, as observed in coagulant assays with crude preparations (27). Considering related clotting factors, granulocyte elastase has been shown to rapidly inactivate the coagulant activities of preparations of Factors VII and XII but not prothrombin (28).

Because of major problems in specificity of studies involving coagulant activities, it was necessary to develop a direct assay for Factor IXa. Accordingly, Factor IX species were bound to solid-phase antibody and the activated form distinguished from the zymogen by use of a labeled inhibitor. Antithrombin III was chosen because it interacts with Factor IXa by a covalentlike bond that forms rapidly in the presence of heparin (29). The enzyme-inhibitor complex also distinguished the activated form from inactive, degraded products of Factor IX. A similar approach has been used to differentiate between inactivation and activation when Factor IX is digested with chymotrypsin and trypsin (20). It has also been used to demonstrate that a mouse monoclonal antibody that reacts to the heavy chain of Factor IXa does not inhibit either Factor XIa activation cleavages and/or subsequent binding of antithrombin III-heparin (21). By detecting generated active sites of Factor IX, the direct assay eliminates the possibility of interference due to effects on Factor VIII as would occur in coagulation or coupled Factor X activation assays.

Elastase can degrade antithrombin III (30), and this effect appears to be operative in the new Factor IXa assay. Therefore, the elastase-specific chloromethyl ketone or α_1 -antitrypsin were used to control for this effect. Even with such control and throughout the time course experiments, elastase-degraded Factor IX was unable to bind antithrombin III. In separate experiments, the procoagulant activity of the Factor IX zymogen was rapidly destroyed. This occurred despite the rapid digestion of Factor IX to form heavy and light chain-sized fragments and only a slower digestion to lower molecular weight fragments (providing calcium was present). Since similarly sized peptide fragments result from elastase and Factor XIa digestions, it appears that elastase hydrolyzes peptide bonds near, but not at, the specific Arg₁₄₅-Ala₁₄₆ and Arg₁₈₀-Val₁₈₁ bonds known to be necessary for activation of Factor IX (31). Indeed, similar to the case with thrombin (32), it is probable that the free amino group of Val₁₈₁, at the amino terminus of the Factor IXa's heavy chain, is necessary for ion pair formation with Asp₃₆₅ to create a functional active site.

The interaction of elastase with Factor IXa produced the same, relatively slower, digestion to lower molecular weight fragments as with the zymogen (see Table II). On the other hand, Factor IXa was only partially inactivated by elastase as indicated by both ^{125}I -antithrombin III-heparin binding and coagulant activity in a nonactivated assay with Factor IX-deficient plasma. The difference of the current results with Factor IXa and those previously reported using crude preparations (27) are best explained by other effects of elastase on the coagulation system. Indeed, when elastase was not inhibited following even brief incubations with Factor IXa, no binding of ^{125}I -antithrombin III was detected. As mentioned previously, this was apparently because of degradative effects of the elastase on antithrombin III. Thus, it appears that Factor IXa is more resistant to inactivation cleavages than is the zymogen. In this regard, studies in which elastase-degraded Factor IX were incubated with Factor XIa are of interest. Although screening for generation of coagulant activity was negative, some ^{125}I -antithrombin binding was observed after short incubations. This presumably relates to the degree of preservation of an active site capable of interacting with either lower molecular weight substrates or less specific inhibitors (including antithrombin III) but sufficient cleavage to destroy secondary binding sites that are needed for physiologic, macromolecular substrates. An analogous situation would be lack of fibrinogen clotting by γ -thrombin despite retention of the ability to bind antithrombin III (33).

The assay using antithrombin III binding to distinguish an active coagulation factor from its zymogen is readily applicable to other coagulation proteins. A similar approach has recently been reported for Factor X (34). Adaptations of these types of assays to more complex conditions, for example, to detect Factor IX activation in plasma, whole blood, or even in vivo, should provide insights into the early steps of coagulation in normal and abnormal hemostasis.

ACKNOWLEDGMENTS

We thank Dr. Daniel Wright, Walter Reed Army Medical Center, for providing granule fractions that were used in preliminary studies. Drs. Powers, Kurachi, and Kiesel are also greatly appreciated for their generous gifts of their preparations.

This work was supported in part by grants from the National Institutes of Health (NHLBI-17265) and from the American Heart Association of Washington (82-WA526).

REFERENCES

- DiScipio, R. G., K. Kurachi, and E. W. Davie. 1978. Activation of human Factor IX (Christmas factor). *J. Clin. Invest.* 61:1528-1538.
- Osterud, B., and S. I. Rapaport. 1977. Activation of factor IX by the reaction product of tissue factor and factor VII. Additional pathway for initiating blood coagulation. *Proc. Natl. Acad. Sci. USA.* 74:5260-5264.
- Kingdon, H. S., J. C. Herion, and P. G. Rausch. 1978. Cellular activation of Factor IX (Christmas factor). *Thromb. Res.* 13:501-507.
- Brower, M. S., and P. C. Harpel. 1983. Alpha-1-antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme linked differential antibody immunosorbent assay in comparison with alpha-2-plasmin inhibitor-plasmin complexes. *Blood.* 61:842-849.
- Plow, E. F. 1982. Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway. *J. Clin. Invest.* 69:564-572.
- Thompson, A. R. 1977. Factor IX antigen by radioimmunoassay. Abnormal Factor IX protein in patients on warfarin therapy and with hemophilia B. *J. Clin. Invest.* 59:900-910.
- Powers, J. C., B. F. Gupton, A. D. Harley, N. Nishino, and R. J. Whitley. 1977. Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. *Biochim. Biophys. Acta* 485:156-166.
- Kurachi, K., and E. W. Davie. 1977. Activation of human factor XI (plasma thromboplastin antecedent) by factor XII_a (activated Hageman factor). *Biochemistry.* 16:5831-5839.
- Mahoney, W. C., K. Kurachi, and M. A. Hermodson. 1980. Formation and dissociation of the covalent complexes between trypsin and two homologous inhibitors, α_1 -antitrypsin and antithrombin III. *Eur. J. Biochem.* 105:545-552.
- Theodorsson, B., U. Hedner, I. M. Nilsson, and W. Kiesel. 1983. A technique for specific removal of factor IX alloantibodies from human plasma: partial characterization of the allo-antibodies. *Blood.* 61:973-981.
- West, B. C., A. S. Rosenthal, N. A. Gelb, and H. R. Kimball. 1974. Separation and characterization of human neutrophil granules. *Am. J. Pathol.* 77:41-66.
- Baugh, R. J., and J. Travis. 1976. Human leukocyte granule elastase: rapid isolation and characterization. *Biochemistry.* 15:836-841.
- Reisfeld, R. A., U. J. Lewis, and D. E. Williams. 1962. Disk electrophoresis of basic proteins and peptides on polyacrylamide gels. *Nature (Lond.).* 195:281-283.
- Fairbanks, G., T. L. Steck, and D. F. H. Wallach. 1971. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. *Biochemistry.* 10:2606-2617.
- Weber, K., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* 244:4406-4412.
- Visser, L., and E. R. Blout. 1972. The use of *p*-nitrophenyl *N*-tert-butylloxycarbonyl-L-alanine as substrate for elastase. *Biochim. Biophys. Acta.* 268:257-260.
- Hummel, B. C. W. 1959. A modified spectrophotometric determination of chymotrypsin, trypsin, and thrombin. *Can. J. Biochem.* 37:1393-1399.
- Silverstein, R. M. 1974. The assay of the bromelains using *N* alpha-CBZ-L-lysine *p*-nitrophenyl ester and *N*-CBZ-glycine *p*-nitrophenyl ester as substrates. *Anal. Biochem.* 62:478-484.
- DiScipio, R. G., M. A. Hermodson, S. G. Yates, and E. W. Davie. 1977. A comparison of human prothrom-

- bin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. *Biochemistry*. 16:698-706.
20. Enfield, D. L., and A. R. Thompson. 1982. Factor IX activation. Cleavage of IX and detection of factor IXa by a novel, active site directed, immunospecific assay. *Circulation*. 66:173.
 21. Thompson, A. R. 1983. Monoclonal antibody to an epitope on the heavy chain of factor IX missing in three hemophilia B patients. *Blood*. 62: In press.
 22. Amphlett, G. W., W. Kisiel, and F. J. Castellino. 1981. The interaction of Ca^{2+} with human Factor IX. *Arch. Biochem. Biophys.* 208:576-585.
 23. Bajaj, S. P. 1982. Cooperative Ca^{2+} binding to human factor IX. Effects of Ca^{2+} on the kinetic parameters of the activation of Factor IX by Factor XIa. *J. Biol. Chem.* 257:4127-4132.
 24. Campbell, E. J., R. M. Senior, J. A. McDonald, and D. L. Cox. 1982. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. *J. Clin. Invest.* 70:845-852.
 25. Osterud, B., B. N. Bouma, and J. H. Griffin. 1978. Human blood coagulation Factor IX. Purification, properties, and mechanism of activation by activated Factor XI. *J. Biol. Chem.* 253:5946-5951.
 26. Zur, M., and Y. Nemerson. 1980. Kinetics of Factor IX activation via the extrinsic pathway. Dependence of K_m on tissue factor. *J. Biol. Chem.* 255:5703-5707.
 27. Karpati, J., K. Varadi, and S. Elodi. 1982. Effect of granulocyte proteases on human coagulation factors IX and X. The protective effect of calcium. *Hoppe-Seyler's Z. Physiol. Chem.* 363:521-525.
 28. Schmidt, W., R. Egbring, and K. Havemann. 1975. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. *Thromb. Res.* 6:315-326.
 29. Rosenberg, J. S., P. W. McKenna, and R. D. Rosenberg. 1975. Inhibition of human Factor IX_a by human antithrombin. *J. Biol. Chem.* 250:8883-8888.
 30. Jochum, M., S. Lander, N. Heimburger, and H. Fritz. 1981. Effect of human granulocyte elastase on isolated human antithrombin III. *Hoppe-Seyler's Z. Physiol. Chem.* 362:103-112.
 31. Kurachi, K., and E. W. Davie. 1982. Isolation and characterization of cDNA coding for human factor IX. *Proc. Natl. Acad. Sci. USA.* 79:6461-6464.
 32. Magnusson, S., and T. Hofmann. 1970. Inactivation of bovine thrombin by nitrous acid. *Can. J. Biochem.* 48:432-437.
 33. Chang, T.-L., R. D. Feinman, B. H. Landis, and J. W. Fenton II. 1979. Anti-thrombin reactions with α - and γ -thrombins. *Biochemistry*. 18:113-119.
 34. Jesty, J., S. A. Morrison, and P. C. Harpel. 1982. Activated factor X-antithrombin complexes: quantification by an enzyme-linked differential antibody immunosorbent assay. *Blood*. 60(Supp. 1):214a. (Abstr.)